Smith & Nephew plc
SN.LHealthcareLSEMedical Devices
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Smith & Nephew plc focuses on Medical Devices services and products. Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company carries a $9.29B market cap, placing it firmly in the mid-cap category. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
Market Cap
$9.29B
Beta
0.67
P/E (TTM)
20.59
P/E (Fwd)
11.82
EPS (TTM)
$0.53
EPS (Fwd)
$0.92
ROE
11.8%
ROA
5.3%
Cash
$557.0M
Total Debt
$3.33B
Free CF
$876.6M
52W Change
1.1%
Annual Financials
Cash vs Debt
Smith & Nephew plc carries $3.33B in total debt against $557.0M in cash reserves — debt is roughly 6.0x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $876.6M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 11.8% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.3% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $5.21B to $6.16B.
SN.L's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Smith & Nephew plc's trajectory.